Table 3.
Treatment for COVID-19 infected cancer patients (n=66)
| Actions | n/N (%) |
|---|---|
| ICU | 16/65 (24.6) |
| Oxygen therapy | 51/64 (79.7) |
| Ventilation | 7/65 (10.7) |
| Antibiotics | |
| Azithromycin | 22/65 (33.9) |
| Meropenemorimipenem | 47/65 (72.3) |
| Vancomycin | 26/65 (40.0) |
| Clindamycin | 2/65 (3.1) |
| Tetracycline | 1/65 (1.5) |
| Cefepime | 2/65 (3.1) |
| Cotrimoxazole | 2/65 (3.1) |
| Colistin | 3/65 (4.6) |
| Metronidazole | 3/65 (4.6) |
| Tobramycin | 4/65 (6.15) |
| Levofloxacin | 20/63 (31.8) |
| Ceftriaxone | 9/65 (13.9) |
| Linesolid | 10/65 (15.4) |
| Antiviral | |
| No drug | 12 (18.46) |
| HCQ | 45 (69.23) |
| Acyclovir | 2 (3.08) |
| Ribavirin | 0 |
| Interferon | 1 (1.54) |
| Acyclovir + HCQ | 4 (6.15) |
| Ribavirin + HCQ | 1 (1.54) |
| Corticosteroid | |
| No drug | 34 (52.31) |
| Dexamethasone | 18 (27.69) |
| Methylprednisolone | 3 (4.62) |
| Hydrocortisone | 2 (3.08) |
| Prednisolone | 0 |
| Dexamethasone + methylprednisolone | 1 (1.54) |
| Dexamethasone + hydrocortisone | 4 (6.15) |
| Prednisolone + methylprednisolone | 1 (1.54) |
| Dexamethasone + methylprednisolone + hydrocortisone | 1 (1.54) |
| Dexamethasone + methylprednisolone + prednisolone | 1 (1.54) |
| Improving clinical symptoms | 52/60 (86.7) |
| Stability symptoms | 1/60 (1.7) |
ICU=Intensive care unit; HCQ=Hydroxychloroquine